![Benjamin Hohl](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 2 M $ in data 31/05/2026
Benjamin Hohl is currently CFO & Head-Corporate Development at Enliven Therapeutics, Inc., a position held since 2023.
Mr. Hohl completed undergraduate education at the University of California, Los Angeles.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 17/06/2026 | 51.000 ( 0,08% ) | 2 M $ | 31/05/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| ENLIVEN THERAPEUTICS, INC. | Direttore Finanziario/CFO | 23/02/2023 |
Attive
Inattive
Società nel listino
Aziende private
| Aziende private | 2 |
|---|---|
University of California, Los Angeles
 University of California, Los Angeles Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Enliven Therapeutics, Inc.
 Enliven Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage precision oncology company that develops molecule therapies | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
